AstraZeneca's diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance | Fierce Pharma
Dapagliflozin biosimilar gets tentative FDA approval - Diabetes Education Services
FORXIGA 5MG TAB – Sulochana Medical Services
FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations | DAIC
Diabetes med Farxiga nabs FDA Priority Review for Chronic Kidney Disease
Jardiance gets parity with Farxiga in US as FDA clears use in heart failure | pharmaphorum
ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma
JDRF Reports: European Commission Has Approved Forxiga for T1D
Savings | FARXIGA® (dapagliflozin) | For HCPs
Two Positive Recommendations by a Regulatory Agency for SGLT Use in Adults with Type 1 Diabetes
New Diabetes Combo Approved | MedPage Today
AZ gets European approvals for Forxiga in chronic kidney disease | pharmaphorum
Forxiga interest widens: AstraZeneca's Forxiga makes ground in EU
ACC 2021: AstraZeneca's Farxiga failed to help COVID-19 patients, but it's safe for them to use | Fierce Pharma
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease | Journal of Investigative Medicine
Forxiga | pharmaphorum
We're All in This Together: Support and Solidarity for Our Heroes on the Front Lines - Union of Concerned Scientists
Farxiga - Dosage, Interactions, FDA Warnings & Studies
A, Change in controlled attenuation parameter (CAP) after treatment... | Download Scientific Diagram
AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet
BMS/AZ resubmits SGLT-2 inhibitor Dapagliflozin to FDA